Angiopoietin-like Proteins
"Angiopoietin-like Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of proteins that is structurally similar to ANGIOPOIETINS but do not bind angiopoietin receptors. They are characterized by an amino-terminal coiled-coil domain, a linker region, and a carboxy-terminal FIBRINOGEN-like domain with the exception of ANGPTL8, which lacks the fibrinogen-like domain. They function in a variety of developmental and physiological processes, including INFLAMMATION, lipid metabolism, hematopoietic stem cell activity, and cancer metastasis.
| Descriptor ID |
D000075802
|
| MeSH Number(s) |
D12.644.276.100.050 D12.776.467.100.050 D23.529.100.050
|
| Concept/Terms |
Angiopoietin-like Proteins- Angiopoietin-like Proteins
- Angiopoietin like Proteins
- Angiopoietin-like Protein
- Angiopoietin like Protein
- Angiopoietin-related Protein
- Angiopoietin related Protein
|
Below are MeSH descriptors whose meaning is more general than "Angiopoietin-like Proteins".
Below are MeSH descriptors whose meaning is more specific than "Angiopoietin-like Proteins".
This graph shows the total number of publications written about "Angiopoietin-like Proteins" by people in this website by year, and whether "Angiopoietin-like Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiopoietin-like Proteins" by people in Profiles.
-
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis. Curr Atheroscler Rep. 2022 12; 24(12):959-967.
-
Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3. Future Cardiol. 2022 02; 18(2):143-153.
-
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr Opin Lipidol. 2021 08 01; 32(4):213-218.
-
Novel therapies for familial hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes. 2021 04 01; 28(2):188-195.
-
Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 08 20; 383(8):711-720.